Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
henagliflozin + retagliptin + metformin
- Development stage
- Phase 4
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This triple combination therapy consists of henagliflozin (an SGLT2 inhibitor), retagliptin (a DPP-4 inhibitor), and metformin (a biguanide). It is being evaluated by Peking University First Hospital in collaboration with Jiangsu Hengrui Pharmaceuticals for the treatment of newly diagnosed type 2 diabetes mellitus. Henagliflozin works by inhibiting sodium-glucose cotransporter-2 (SGLT2) in the kidneys to reduce glucose reabsorption. Retagliptin inhibits dipeptidyl peptidase-4 (DPP-4), thereby increasing incretin levels to stimulate insulin secretion. Metformin reduces hepatic glucose production and improves insulin sensitivity. The combination is currently being studied in a Phase 4 trial to compare initial triple therapy against a sequential treatment approach.
- Other names
- Henagliflozin Proline + Retagliptin + MetforminHenagliflozin + Retagliptin + MetforminHenggliptin + Retagliptin + MetforminRegagliptin + Henagliflozin + MetforminRuigeliflozin + Henagliflozin + MetforminHenggeliflozin + Retagliptin + Metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on henagliflozin + retagliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on henagliflozin + retagliptin + metformin.